Radiotherapy is a key component of glioblastoma therapy, however, difficulties in delivering high doses to tumours cells while preserving healthy tissues risks limits its success. Here, the authors report a phase I dose escalation study investigating convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL), chelated-186Re encapsulated in nanoliposomes, in patients with recurrent, high-grade malignant glioma.
- Andrew J. Brenner
- Toral Patel
- John R. Floyd
